AU2021268757B2 - Peptide tags and binding partners - Google Patents

Peptide tags and binding partners

Info

Publication number
AU2021268757B2
AU2021268757B2 AU2021268757A AU2021268757A AU2021268757B2 AU 2021268757 B2 AU2021268757 B2 AU 2021268757B2 AU 2021268757 A AU2021268757 A AU 2021268757A AU 2021268757 A AU2021268757 A AU 2021268757A AU 2021268757 B2 AU2021268757 B2 AU 2021268757B2
Authority
AU
Australia
Prior art keywords
seq
binding partner
peptide tag
homology
identity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021268757A
Other languages
English (en)
Other versions
AU2021268757A1 (en
Inventor
Adam Frederik Sander BERTELSEN
Cyrielle Elyette FOUGEROUX
Susan THRANE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adaptvac Aps
Original Assignee
Adaptvac Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adaptvac Aps filed Critical Adaptvac Aps
Publication of AU2021268757A1 publication Critical patent/AU2021268757A1/en
Application granted granted Critical
Publication of AU2021268757B2 publication Critical patent/AU2021268757B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
AU2021268757A 2020-05-07 2021-05-07 Peptide tags and binding partners Active AU2021268757B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20173377 2020-05-07
EP20173377.1 2020-05-07
PCT/EP2021/062113 WO2021224451A1 (en) 2020-05-07 2021-05-07 Peptide tags and binding partners

Publications (2)

Publication Number Publication Date
AU2021268757A1 AU2021268757A1 (en) 2022-12-08
AU2021268757B2 true AU2021268757B2 (en) 2026-07-09

Family

ID=70613720

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021268757A Active AU2021268757B2 (en) 2020-05-07 2021-05-07 Peptide tags and binding partners

Country Status (11)

Country Link
US (1) US20230321260A1 (enExample)
EP (1) EP4146675A1 (enExample)
JP (2) JP7843245B2 (enExample)
KR (1) KR20230006473A (enExample)
CN (1) CN115698045A (enExample)
AU (1) AU2021268757B2 (enExample)
BR (1) BR112022019632A2 (enExample)
CA (1) CA3177709A1 (enExample)
IL (1) IL297111A (enExample)
MX (1) MX2022013938A (enExample)
WO (1) WO2021224451A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016207099C1 (en) 2015-01-15 2021-02-04 University Of Copenhagen Virus-like particle with efficient epitope display
WO2022229817A1 (en) * 2021-04-28 2022-11-03 Bavarian Nordic A/S Vaccines comprising virus-like particles displaying sars-cov-2 antigens and methods of use
US20240240203A1 (en) 2021-05-04 2024-07-18 SpyBiotech Limited Adenoviral vectors and vaccines thereof
WO2024068265A2 (en) 2022-09-30 2024-04-04 Bavarian Nordic A/S Virus-like particles displaying sars-cov-2 antigens as booster vaccines and uses thereof
CN116165377A (zh) * 2023-04-21 2023-05-26 常州伯仪生物科技有限公司 一种通过竞争elisa法进行标签蛋白定量的方法
WO2025097030A1 (en) * 2023-11-02 2025-05-08 Oregon State University Virus-like particles displaying neisseria gonorrhoeae antigens and use thereof for immunization against gonorrhea
GB202317925D0 (en) 2023-11-23 2024-01-10 Spybiotech Ltd Vaccines
CN117723749B (zh) * 2024-02-07 2024-06-04 南昌大学 基于分子粘合剂的动态光散射免疫传感检测方法
WO2026039325A2 (en) 2024-08-12 2026-02-19 Regeneron Pharmaceuticals, Inc. Modified mtm1 genes and uses thereof
WO2026119880A1 (en) * 2024-12-02 2026-06-11 Adaptvac Aps Vaccine for inducing antibodies to inhibit thymic stromal lymphopoietin
WO2026119878A1 (en) * 2024-12-02 2026-06-11 Adaptvac Aps Vaccine for inducing antibodies to inhibit native interleukin-11 signaling

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201002362D0 (en) 2010-02-11 2010-03-31 Isis Innovation Peptide tag systems that spontaneously form an irreversible link to protein partners via isopeptide bonds
CA2964119C (en) * 2014-11-03 2022-10-18 Merck Patent Gmbh Soluble intein fusion proteins and methods for purifying biomolecules
AU2016207099C1 (en) 2015-01-15 2021-02-04 University Of Copenhagen Virus-like particle with efficient epitope display
GB201509782D0 (en) * 2015-06-05 2015-07-22 Isis Innovation Methods and products for fusion protein synthesis
US11807671B2 (en) * 2016-11-16 2023-11-07 Auckland Uniservices Limited Methods for protein ligation and uses thereof
CN111073925B (zh) * 2018-10-19 2022-04-26 北京大学 一种基于无序蛋白偶联酶的高效多肽-多肽偶联系统和方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
B. ZAKERI ET AL: "Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 109, no. 12, 20 March 2012 (2012-03-20), pages E690 - E697 *
LEE LING TAN, SHAWN S. HOON, FONG T. WONG: "Kinetic Controlled Tag-Catcher Interactions for Directed Covalent Protein Assembly", PLOS ONE, vol. 11, no. 10, pages e0165074, XP055705262, DOI: 10.1371/journal.pone.0165074 *
YAJIE LIU ET AL: "Tuning SpyTag-SpyCatcher mutant pairs toward orthogonal reactivity encryption", CHEMICAL SCIENCE, vol. 8, no. 9, 1 January 2017 (2017-01-01), United Kingdom, pages 6577 - 6582 *

Also Published As

Publication number Publication date
EP4146675A1 (en) 2023-03-15
KR20230006473A (ko) 2023-01-10
AU2021268757A1 (en) 2022-12-08
BR112022019632A2 (pt) 2023-10-03
CN115698045A (zh) 2023-02-03
CA3177709A1 (en) 2021-11-11
MX2022013938A (es) 2022-11-30
JP2026048917A (ja) 2026-03-17
WO2021224451A1 (en) 2021-11-11
JP7843245B2 (ja) 2026-04-09
JP2023525752A (ja) 2023-06-19
IL297111A (en) 2022-12-01
US20230321260A1 (en) 2023-10-12
WO2021224451A9 (en) 2022-05-27